← brief for 2026-11-03 · Slowing decline

Bexagliflozin: pharmacological profile and clinical applications of a sodium-glucose cotransporter 2 inhibitor.

Article No results yet Peer reviewed

Key takeaways

This is a review of a new diabetes drug called bexagliflozin. It summarizes what is known about how the drug works and its effects. It notes that this specific drug has not yet been tested in large trials for heart or kidney outcomes. There are no new results from a specific experiment in this piece.

Who did this work

Gars A · Khan A · Kim S · Dodge C · Tinna H · Li Z · Gupta A

Source

Article · PubMed, the drug frontier · 2026 Nov 4
https://pubmed.ncbi.nlm.nih.gov/42975136/